These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 20232284)

  • 1. GP96 C-terminal improves Her2/neu DNA vaccine.
    Pakravan N; Soleimanjahi H; Hassan ZM
    J Gene Med; 2010 Apr; 12(4):345-53. PubMed ID: 20232284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
    Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
    Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant activity of GP96 C-terminal domain towards Her2/neu DNA vaccine is fusion direction-dependent.
    Pakravan N; Hashemi SM; Hassan ZM
    Cell Stress Chaperones; 2011 Jan; 16(1):41-8. PubMed ID: 20730610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coexpression of Flt3 ligand and GM-CSF genes modulates immune responses induced by HER2/neu DNA vaccine.
    Yo YT; Hsu KF; Shieh GS; Lo CW; Chang CC; Wu CL; Shiau AL
    Cancer Gene Ther; 2007 Nov; 14(11):904-17. PubMed ID: 17704754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice.
    Jacob J; Radkevich O; Forni G; Zielinski J; Shim D; Jones RF; Wei WZ
    Cell Immunol; 2006 Apr; 240(2):96-106. PubMed ID: 16930573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of adjuvant activity of N- and C-terminal domain of gp96 in a Her2-positive breast cancer model.
    Pakravan N; Hassan ZM
    Cell Stress Chaperones; 2011 Jul; 16(4):449-57. PubMed ID: 21359667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA vaccination against neu reduces breast cancer incidence and metastasis in mice.
    Lachman LB; Rao XM; Kremer RH; Ozpolat B; Kiriakova G; Price JE
    Cancer Gene Ther; 2001 Apr; 8(4):259-68. PubMed ID: 11393278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced immunogenicity of HPV16E7 accompanied by Gp96 as an adjuvant in two vaccination strategies.
    Bolhassani A; Zahedifard F; Taghikhani M; Rafati S
    Vaccine; 2008 Jun; 26(26):3362-70. PubMed ID: 18471945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.
    Chan T; Sami A; El-Gayed A; Guo X; Xiang J
    Gene Ther; 2006 Oct; 13(19):1391-402. PubMed ID: 16724093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor endothelial marker 8 enhances tumor immunity in conjunction with immunization against differentiation Ag.
    Felicetti P; Mennecozzi M; Barucca A; Montgomery S; Orlandi F; Manova K; Houghton AN; Gregor PD; Concetti A; Venanzi FM
    Cytotherapy; 2007; 9(1):23-34. PubMed ID: 18236207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmented humoral and cellular immune response of hepatitis B virus DNA vaccine by micro-needle vaccination using Flt3L as an adjuvant.
    Zhou Q; Wang F; Yang F; Wang Y; Zhang X; Sun S
    Vaccine; 2010 Feb; 28(5):1357-62. PubMed ID: 19932674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
    Sakai Y; Morrison BJ; Burke JD; Park JM; Terabe M; Janik JE; Forni G; Berzofsky JA; Morris JC
    Cancer Res; 2004 Nov; 64(21):8022-8. PubMed ID: 15520211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2/neu DNA vaccination for breast tumors.
    Smorlesi A; Papalini F; Pierpaoli S; Provinciali M
    Methods Mol Biol; 2008; 423():473-85. PubMed ID: 18370223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
    Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W
    J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor.
    Chen Z; Huang H; Chang T; Carlsen S; Saxena A; Marr R; Xing Z; Xiang J
    Cancer Gene Ther; 2002 Sep; 9(9):778-86. PubMed ID: 12189528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies.
    Dela Cruz JS; Trinh KR; Chen HW; Ribas A; Morrison SL; Penichet ML
    Mol Immunol; 2006 Feb; 43(6):667-76. PubMed ID: 15908002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas.
    Gu XG; Schmitt M; Hiasa A; Nagata Y; Ikeda H; Sasaki Y; Akiyoshi K; Sunamoto J; Nakamura H; Kuribayashi K; Shiku H
    Cancer Res; 1998 Aug; 58(15):3385-90. PubMed ID: 9699670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.
    Sloots A; Mastini C; Rohrbach F; Weth R; Curcio C; Burkhardt U; Jäger E; Forni G; Cavallo F; Wels WS
    Clin Cancer Res; 2008 Nov; 14(21):6933-43. PubMed ID: 18980988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.